Trials / Completed
CompletedNCT05281510
Study of VRC07-523LS, CAP256V2LS, and Vesatolimod, in Early Antiretroviral-treated HIV-1 Clade C-infected Women
A Phase 2a Study to Evaluate the Safety and Tolerability of a Regimen of Dual Anti-HIV Envelope Antibodies, VRC07-523LS and CAP256V2LS, in a Sequential Regimen With a TLR7 Agonist, Vesatolimod, in Early Antiretroviral-Treated HIV-1 Clade C-Infected Women
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Gilead Sciences · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The goals of this clinical study are to learn more about the study drugs, VRC07-523LS, CAP256V2LS, and vesatolimod (VES) and how safe it is in women that have HIV and are on antiretroviral therapy (ART).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Vesatolimod | Administered orally |
| BIOLOGICAL | VRC07523LS | Administered intravenously |
| BIOLOGICAL | CAP256V2LS | Administered intravenously |
Timeline
- Start date
- 2022-06-09
- Primary completion
- 2025-01-16
- Completion
- 2025-01-16
- First posted
- 2022-03-16
- Last updated
- 2026-01-16
- Results posted
- 2026-01-16
Locations
1 site across 1 country: South Africa
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05281510. Inclusion in this directory is not an endorsement.